You are currently viewing a new version of our website. To view the old version click .

Topic Information

Dear Colleagues,

Bladder cancer is the ninth most common malignant ailment and the fourteenth most common cause of cancer death worldwide. Over the past decades, novel and potent agents have been developed and approved. However, although innovative approaches, such as targeted therapy and/or immunotherapy, have provided benefits for tumor patients, many challenges, such as low response rate and drug resistance, remain overt. Extensive research is required to refine and optimize the current bladder cancer treatment protocols. Dissatisfaction with the conventional treatment has meanwhile driven many cancer patients to seek “non-conventional” care options, including natural products, mind and body practices, or other non-conventional health approaches. From the scientists’ side, innovative and “risky” projects are under investigation focusing on cancer stem cell targeting, selective photodynamic technology, or anticancer vaccine therapy, among others. The purpose of this Special Issue is to collect original research articles and reviews on non-conventional medicine for bladder cancer. Both clinical trials and preclinical studies (in vitro and in vivo) are welcome that do not reflect the mainstream of cancer treatment but which are rather original and may open the mind for unconventional strategies.

Prof. Dr. Roman Blaheta
Prof. Dr. Beatrice E. Bachmeier
Topic Editors

Keywords

  • bladder cancer
  • non-mainstream treatment
  • complementary medicine
  • plant compounds
  • stem cell targeting
  • anticancer vaccination
  • photodynamic therapy

Participating Journals

Biomolecules
Open Access
12,039 Articles
Launched in 2011
4.8Impact Factor
9.2CiteScore
19 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Cancers
Open Access
33,909 Articles
Launched in 2009
4.4Impact Factor
8.8CiteScore
20 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
Current Oncology
Open Access
5,046 Articles
Launched in 1994
3.4Impact Factor
4.9CiteScore
21 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
International Journal of Molecular Sciences
Open Access
104,616 Articles
Launched in 2000
4.9Impact Factor
9.0CiteScore
20 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Onco
Open Access
129 Articles
Launched in 2021
-Impact Factor
-CiteScore
21 DaysMedian Time to First Decision
-Highest JCR Category Ranking

Published Papers